Feb 10, 2026
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360◦ Conference
Dec 12, 2025
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving…
Dec 11, 2025
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing…
Jun 27, 2025
Med (Cell Press) 2025
Sep 19, 2024
Lancet Respiratory Medicine 2024
Sep 14, 2023
JNCCN 2023
Nov 16, 2025
PP01.45: Phase 3 Study of Plinabulin/Docetaxel vs. Docetaxel in 2L/3L…
Oct 23, 2025
Phase 2 study of pembrolizumab (Pemb) plus plinabulin (Plin) and…
Sep 10, 2025
Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with…
Sep 09, 2021
Plinabulin in combination with G-CSF is undergoing regulatory review for…
Sep 08, 2021
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) — BeyondSpring Inc.…
Sep 07, 2021
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) — BeyondSpring Inc.…
Sep 03, 2021
09.2021 European Society for Medical Oncology (ESMO) Congress (2021) Severe…
Aug 31, 2021
Topline results, released in early August, demonstrated improvement in overall…
Aug 26, 2021
Wanchunbulin, BeyondSpring’s 58%-owned subsidiary in China, to partner with Hengrui,…
Aug 10, 2021
Distinguished industry executive and entrepreneur recognized for the development of…
Aug 04, 2021
08.04.2021 View webcast
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) — BeyondSpring (the…
Email us at
Call us at
Office location